Decortin H

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Decortin H

Property Description
Active ingredient Prednisolone Acetate
Form Tablet (Oral)
Pharmacological class Glucocorticoid (Corticosteroid)
General Purpose Systemic anti-inflammatory and immunosuppressive
Origin Synthetic steroid analogue

Decortin H is a prescription-only pharmaceutical preparation defined by its active ingredient, Prednisolone Acetate, which belongs to the potent class of Glucocorticoids. This specific formulation is distinguished by its oral tablet form, making it suitable for systemic treatment in adults and children when determined necessary by a physician.


What Type of Medicine is Decortin H?

Decortin H is classified as a Glucocorticoid, a potent subset of Corticosteroids. This pharmacological class is derived from, but is distinct from, the natural hormone Cortisol (Hydrocortisone) produced by the adrenal glands. The medication is a synthetic steroid, chemically engineered as an analogue to produce a powerful and consistent therapeutic action across the body's systems. This classification reflects its role as a systemic anti-inflammatory agent, and the medicine is clinically recognized for its ability to help manage severe inflammation and suppress the immune system.

Composition and Form: The Role of Prednisolone Acetate

The essential component of Decortin H is the Prednisolone Acetate compound, which is formulated as a single-ingredient product. For systemic use, Decortin H is typically presented as an oral tablet, enabling the active substance to be absorbed throughout the body. Prednisolone Acetate is an ester of the clinically active drug Prednisolone, a structural distinction that informs its formulation properties and ensures efficient systemic delivery following oral administration. The Glucocorticoid group is characterized by its ability to regulate systemic inflammation.

What is the General Purpose of This Glucocorticoid?

The overall purpose of this medicine is to utilize its inherent anti-inflammatory and immunosuppressive properties to quickly mitigate and control biological reactions that are damaging tissues. For instance, it is commonly used in scenarios requiring immediate and comprehensive control over severe allergic states or flare-ups of chronic autoimmune conditions. The ultimate benefit is the rapid reduction of symptoms caused by severe inflammation, such as swelling and pain, thereby preserving tissue integrity and function during acute or chronic inflammatory episodes.

What side effects are possible with Decortin H?

Possible Side Effects and Safety Information

The safety profile of Decortin H (prednisolone) includes a wide range of documented adverse reactions, classified by the body system affected and often linked to the duration and dose of treatment.

Adverse Reaction Scope

Category Documented Effects
System-Organ Classes Effects on metabolism (e.g., altered glucose tolerance, weight gain), fluid/electrolyte balance (e.g., fluid retention, hypertension), musculoskeletal, gastrointestinal (GI), ophthalmic, and psychiatric systems.
Serious Adverse Reactions Officially highlighted serious events include GI ulceration with potential hemorrhage or perforation, severe psychiatric disturbances (e.g., psychosis, severe depression), adrenal suppression, aseptic necrosis of bone (e.g., femoral heads), and certain infections.
Dose- or Exposure-Related Patterns The risk for certain significant events, such as bone density loss (osteoporosis), cataracts, and adrenal gland suppression, is explicitly associated with higher doses and long-term, chronic use. Gradual dose reduction (tapering) is officially required after prolonged therapy to minimize the risk of withdrawal symptoms and adrenal insufficiency.

Population-Specific Safety Considerations

Formal warnings note the risk of growth retardation in pediatric patients with long-term administration. Safety considerations for pregnant individuals include the potential for fetal harm, particularly with first-trimester use. The drug may also increase the need for blood glucose management agents in patients with diabetes mellitus.

Safety-Related Restrictions or Limitations

Decortin H is formally contraindicated in patients with known hypersensitivity to the drug and in those with systemic fungal infections. Specific caution and monitoring are required in individuals with pre-existing conditions such as hypertension, congestive heart failure, diabetes, osteoporosis, peptic ulcer disease, and existing psychiatric illnesses.

Overdose and Emergency Response

Overdose and When to Seek Help

The information regarding overdose of Prednisolone Acetate (Decortin H) is primarily based on official regulatory documentation.


Documented Overdose Manifestations and Risks

Feature Official Regulatory Statements
Acute Overdose Acute ingestion is generally rare. Acute signs may include disturbances in fluid and electrolyte balance, such as hypernatremia and edema [Based on DailyMed/MHRA].
Chronic Overexposure Prolonged, high-dose overexposure leads to systemic hypercortisolism, often presenting as Cushingoid features, hypertension, and hyperglycemia [Based on EMA SmPC].
Severe Outcome The most serious documented outcome is adrenal suppression (HPA axis suppression), which risks a potentially life-threatening adrenal crisis upon abrupt cessation [Based on FDA Prescribing Information].

Emergency Actions and Management

Suspected overdose requires that individuals seek immediate medical attention and contact a Poison Control Center immediately [Based on NIH MedlinePlus/DailyMed]. No specific antidote is known for this glucocorticoid overdose [Based on FDA Labeling].

Regulatory guidance states that management involves primarily symptomatic and supportive treatment. Hospital monitoring is required, with specific attention given to observing and correcting fluid and electrolyte balance and overall clinical status [Based on DailyMed]. Procedures such as gastric emptying may be considered in cases of acute, massive ingestion, depending on the circumstances [Based on MHRA Guidance].

Therapeutic Uses of Decortin H

What Decortin H Treats: Main Uses and Benefits

Decortin H is commonly used to provide symptomatic relief across domains where additional symptomatic support is needed, relevant in contexts marked by increased discomfort or tension associated with inflammatory or irritative processes. This medication is applied in addressing conditions that affect the skin, eyes, lungs, and joints. It is relevant in clinical settings that involve acute or unstable symptom patterns, such as conditions characterized by periods of heightened symptoms, conditions involving recurrent or episodic manifestations, and episodic breathing difficulties.

It helps address symptom clusters that may become more disruptive during flare-ups, including severe swelling, stiffness, and associated pain. The medicine is commonly used to help manage these issues in conditions like certain types of arthritis, asthma exacerbations, and certain autoimmune conditions. The primary benefit is easing this discomfort, which contributes to improved comfort during periods of heightened symptoms.

“This medication is applied when symptoms create noticeable functional strain and short-term symptomatic assistance is needed.”

Quick Fact: Relief for Intense Discomfort and Disruptive Symptom Clusters

Regulatory References

  1. NIH MedlinePlus overview on Prednisolone

Eligibility and Restrictions for Use

Population Eligibility Rules for Decortin H (Prednisolone Acetate)

Official regulatory documents define strict criteria for patient eligibility, differentiating between absolute contraindications and conditions requiring conditional use. Eligibility is determined based on the patient's existing health status, age, and physiological state.


Who Must Not Use Decortin H (Contraindications)

Decortin H is contraindicated in patients with a known systemic fungal infection that is untreated, or known hypersensitivity to prednisolone or any component of the formulation. Additionally, the medicine is contraindicated for patients receiving live or live-attenuated vaccines during treatment with immunosuppressive doses.


Populations Requiring Restricted or Conditional Use

Use is restricted or requires careful medical assessment in patients with specific conditions, including an active peptic ulcer, certain viral infections (such as Herpes simplex), latent tuberculosis, severe uncontrolled hypertension, or severe osteoporosis.

Age and Physiological Status:

  • Pediatric Patients: Generally eligible, but prolonged therapy requires monitoring of growth and development.
  • Pregnancy and Lactation: Use is generally not recommended or requires a formal assessment to determine if the potential benefits outweigh the documented risks to the fetus or infant, as the medicine can appear in breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Decortin H (Prednisolone Acetate) outlines specific pharmacokinetic and pharmacodynamic interaction patterns with co-administered substances. These interactions may alter drug exposure or result in additive pharmacological effects, as documented by government health authorities.

Pharmacokinetic Interactions (Metabolism)

Prednisolone is metabolized by the CYP 3A4 enzyme. Co-administration with CYP 3A4 inhibitors (such as Ketoconazole) may increase the systemic exposure of Prednisolone by decreasing its clearance. Conversely, CYP 3A4 inducers (such as Rifampin or Phenytoin) may decrease the systemic exposure of Prednisolone by increasing its clearance. Prednisolone itself can also act as a moderate CYP 3A4 inducer, potentially decreasing the plasma concentration of sensitive co-administered substrates.

Pharmacodynamic Interactions

Interaction Type Interacting Agents (Examples) Official Outcome
Additive Risk (GI) Nonsteroidal Anti-Inflammatory Agents (NSAIDs) Increased risk of gastrointestinal side effects.
Additive Risk (Electrolyte) Potassium-Depleting Agents (Diuretics) Increased risk of hypokalemia (low potassium).
Metabolic Effect Antidiabetic Agents (Insulin, Oral Hypoglycemics) Potential to increase blood glucose concentrations.

Specific Restrictions

Do not administer Live or Live Attenuated Vaccines to patients receiving immunosuppressive doses of corticosteroids. Regulatory documents note that the drug's effects may be enhanced in patients with cirrhosis due to decreased metabolism.

Mechanism of Action

Decortin H (Prednisolone Acetate) exerts its effect by globally modulating gene transcription through its primary biological target, the Glucocorticoid Receptor ( GR), which results in systemic anti-inflammatory and immunosuppressive effects.

Nuclear Signaling and Gene Expression Control

This mechanism involves the drug acting as an agonist for the intracellular GR, creating a complex that enters the cell nucleus to influence the cell’s genetic code. This action achieves Transrepression of pro-inflammatory transcription factors ( NF-kappa B) while simultaneously promoting Transactivation of genes for anti-inflammatory proteins, resulting in a significant alteration of cellular signaling.

Inhibition of Inflammatory Cascades

The transcriptional changes initiate a sequence that significantly disrupts key biochemical processes, most notably the Arachidonic Acid Cascade. By indirectly inhibiting the PLA2 enzyme, the drug prevents the formation of inflammatory mediators like prostaglandins and leukotrienes, contributing to decreased vascular permeability and reduced tissue fluid accumulation.

Systemic Immunosuppressive Modulation

The combined molecular action leads to systemic effects on the immune system, including the promotion of apoptosis (programmed cell death) in specific immune cells and the redistribution of circulating T-lymphocytes and monocytes. This dampens the overall capacity for immune and inflammatory responses, which represents the primary physiological effect of this mechanism.

Dosage and Administration Information

How to Use Decortin H

Decortin H, which contains Prednisolone Acetate and is taken as an oral tablet, is used for systemic treatment following high-level administration principles. The entire usage protocol is highly variable and depends on the individual therapeutic response.


Official Usage Principles and Regimens

The fundamental principle of use is the individualization of dosage, meaning no fixed dosage applies to all patients. Initial dosing typically ranges from 5 mg to 60 mg of prednisolone (or its equivalent) per day. Following a satisfactory response, the dosage is reduced in small, timely decrements until the lowest maintenance dose is achieved.

Usage Feature Labeled Instruction
Route Oral (taken by mouth).
Frequency Pattern Once daily or in divided doses. Long-term use may utilize Alternate-Day Therapy (ADT).
Withdrawal Dosage must be tapered gradually upon discontinuation after long-term use, never stopped abruptly.
Stress Dosing An increased dose is indicated before, during, and after a patient experiences unusual physical stress (e.g., trauma or surgery).

These official instructions define the required process for starting, adjusting, and ending the medication course. The medication is not used with a static dose but requires careful and responsive management throughout the treatment period.

Recent Clinical Evidence

Decortin H: Recent Clinical Evidence

Evidence for Use in Managing Acute Inflammatory Flares in Rheumatoid Arthritis

The research foundation utilizes Randomized Controlled Trials (RCTs) and larger meta-analyses to explore this medicine's use in adults with active rheumatoid arthritis (RA). These studies focus on patient groups experiencing fluctuating or unstable symptoms. Research primarily explores changes in disease activity scores and shifts in inflammation biomarkers. Studies reported measurements of disease activity scores that reflected changes observed during short-term administration. Research provides insight into these short-term changes, and some long-term observational studies have monitored how joint status evolved over multiple years. Studies indicate that data for certain groups remain insufficient, particularly regarding long-term effects after treatment is concluded.

Evidence for Use in Acute Asthma Exacerbations

Evidence for use during sudden, severe worsening of asthma symptoms comes mainly from short-term RCTs and systematic reviews. These trials was studied for both adults and children with episodic manifestations. Research examined lung function measures (such as FEV1) and monitored outcomes related to systemic imbalance, such as the need for hospitalization or emergency department care. Clinical trials reported data related to lung function measurements that were observed over the very short treatment period (typically less than two weeks). Studies monitored how outcomes describing acute changes were observed during the administration period.

Research Gaps and Limitations

The existing evidence base, while extensive in some areas, presents several limitations. Long-term effects are not fully established, especially concerning the cumulative impact of repeated, short treatment cycles over time. The evidence quality varies across studies, and for many less common indications, comparative evidence is lacking. Sample sizes were modest in some specific trials, meaning the results apply only to the populations studied and research provides context but not individual predictions.

Key Studies & References

  1. FDA Labeling: PREDNISOLONE tablet - DailyMed (Used for indications and general drug class context)

Frequently Asked Questions (FAQ)

Common questions about Decortin H (FAQ)


Q: What is the main difference between Decortin H and regular Decortin?

Decortin H contains Prednisolone Acetate, which is a specific chemical formulation known as an ester of the active drug, prednisolone. This distinction is related to how the medicine is prepared and delivered for systemic use, according to official regulatory documentation.


Q: How quickly can a person generally expect Decortin H to start working?

As a general principle, corticosteroids are expected to help suppress the body's inflammatory response. Official usage protocols describe that initial dosage adjustments are made based on when a satisfactory response is noted during clinical supervision.


Q: Is it true that Decortin H can affect sleep patterns?

Yes, official safety information indicates that insomnia (trouble sleeping) is a documented side effect. It is categorized with other central nervous system effects, which can also include changes such as feelings of euphoria or mood swings.


Q: Can Decortin H cause weight changes in some people?

Official information documents that Decortin H can affect metabolism. Specific documented effects include increased appetite and resulting weight gain in some individuals.


Q: Are there any common foods or drinks that should be avoided while using Decortin H?

While regulatory sources do not widely document specific food avoidance, official usage instructions often mention taking the oral tablet with food to help minimize the possibility of stomach upset.


Q: Is Decortin H safe for long-term use, based on research?

The risk of certain significant adverse reactions is explicitly associated with higher doses and long-term, chronic use of the medication. These effects include the potential for bone density loss and adrenal gland suppression, which are typically managed through close monitoring.


Q: Are there documented interactions between Decortin H and pain relievers like ibuprofen?

Yes, Decortin H has a documented additive risk interaction with Nonsteroidal Anti-Inflammatory Agents (NSAIDs), a class that includes ibuprofen. This combination may lead to an increased risk of gastrointestinal side effects.


Q: What kind of research has been done on Decortin H for autoimmune disorders?

Regulatory documents state the drug is indicated for use as an anti-inflammatory or immunosuppressive agent in managing certain autoimmune disorders. Examples of conditions covered include rheumatoid arthritis and ulcerative colitis.


Q: Does Decortin H affect blood sugar levels?

Yes, official warnings indicate that corticosteroids may cause hyperglycemia (elevated blood sugar). This can potentially lead to the manifestation of latent diabetes or increase the required amount of blood sugar management medicine for people with diabetes.


Q: Is it typical to feel increased energy or restlessness when first taking Decortin H?

Official documentation notes that effects on the psychiatric system may occur, including euphoria (which is sometimes described as increased energy) and general mood swings. These effects relate to how the drug impacts the central nervous system.


Q: Can Decortin H be used by people who have high blood pressure?

Individuals with pre-existing conditions such as hypertension (high blood pressure) or congestive heart failure are populations for whom specific caution and monitoring are noted in official safety guidelines.


Q: Why might a doctor prescribe Decortin H instead of other similar medications?

Official regulatory sources highlight that prednisolone, the active ingredient, is a potent glucocorticoid. On a weight basis, it has been described to have multiple times the anti-inflammatory potency of hydrocortisone.


Q: How is Decortin H different from a regular anti-inflammatory medicine?

Decortin H is classified as a glucocorticoid that works by providing systemic anti-inflammatory action through immunosuppressive effects. This mechanism is distinct from that of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), which work through a different biochemical pathway.


Q: What is the 'H' in Decortin H for?

The 'H' in Decortin H often references the specific Acetate part of the active ingredient, Prednisolone Acetate. The acetate part is a specific chemical tag that affects how the drug is formulated and delivered.


Q: Is Decortin H commonly used to treat allergies?

Yes, the official indications for use include managing certain allergic states. This encompasses severe conditions such as seasonal or perennial allergic rhinitis that require systemic anti-inflammatory or immunosuppressive treatment.


Q: What is the purpose of Decortin H in the treatment of inflammatory bowel disease?

The medicine is indicated for use in managing certain inflammatory conditions of the digestive system. This includes flare-ups of inflammatory bowel diseases such as ulcerative colitis.


Q: Are there any reports of Decortin H causing vision changes?

Official warnings document that ophthalmic (eye) effects may occur, which can potentially lead to changes in vision. These effects include the development of cataracts and glaucoma.


Q: Can Decortin H affect mood or cause emotional changes?

Yes, official warnings state that behavioral and mood disturbances may occur during use. These can range from feelings of euphoria or insomnia to more severe reactions like deep depression or psychosis.

--UNSAFE

Q: Does Decortin H have documented interactions with alcohol?

While specific pharmacokinetic interactions are not typically listed, official regulatory sources note that combining the drug with alcohol may increase the potential for certain shared side effects, such as gastrointestinal irritation.


Q: Why might a patient experience a 'rebound' effect after stopping Decortin H?

The gradual dose reduction, or tapering, upon discontinuation is a standard protocol intended to minimize the risk of withdrawal symptoms and adrenal insufficiency. These issues are related to the body's hormonal systems adjusting when the drug is stopped.


Q: Is Decortin H used for joint pain and arthritis?

Yes, the medicine is officially indicated for use in managing inflammatory conditions. This includes certain types of rheumatoid arthritis, where it is used to help control inflammation and pain.


Q: Do official sources mention any risk of bone density loss with Decortin H use?

Yes, official warnings specify that decreases in bone density (osteoporosis) are a known risk. This risk is primarily associated with patients receiving long-term corticosteroid therapy.


Q: Is Decortin H an immunosuppressant?

Yes, Decortin H is classified as a glucocorticoid. It is officially indicated for use because it functions as both an anti-inflammatory agent and an immunosuppressive agent.


Q: Can Decortin H cause gastrointestinal issues?

Yes, official documentation lists gastrointestinal effects, including a risk of peptic ulceration. Severe instances could involve potential hemorrhage or perforation, which is why precautions are necessary.


Q: Is it a common observation that Decortin H causes increased appetite?

Yes, official regulatory documentation lists increased appetite and subsequent weight gain as documented adverse reactions related to how the medicine affects the body’s metabolism.


Q: Why is it important for doctors to know about all medications taken with Decortin H?

This medicine interacts with many other substances, including certain other drugs, which can alter the body's exposure to Decortin H. This knowledge helps manage the risk of serious side effects or changes in efficacy.


Q: Is it necessary to finish all the Decortin H prescribed, even if symptoms improve quickly?

Official regulatory instructions define that the dosage must be tapered gradually upon discontinuation after long-term use. The medicine should not be stopped abruptly to prevent potential withdrawal symptoms.


Q: Is it standard to have routine blood tests while using Decortin H?

Monitoring is noted as a necessary precaution for patients on chronic use. This typically includes checking for elevated blood pressure and monitoring sodium and potassium serum levels due to the drug’s potential effect on fluid and electrolyte balance.


Q: Does the time of day a person uses Decortin H matter?

The official usage principles state that the drug may be taken once daily or in divided doses. For long-term use, protocols like Alternate-Day Therapy (ADT) are used, which require specific timing.


Q: Can Decortin H be used for asthma or breathing difficulties?

Yes, the medicine is officially indicated for use as an anti-inflammatory or immunosuppressive agent for certain respiratory diseases. This includes managing conditions such as acute asthma exacerbations.


Q: Is Decortin H available over-the-counter in some countries?

According to official drug classifications, Decortin H (Prednisolone Acetate) is formally classified as a prescription-only pharmaceutical preparation.


Q: Are there any known drug-disease interactions for Decortin H?

Yes, official safety guidelines require specific caution in patients with certain pre-existing conditions. These include hypertension, congestive heart failure, diabetes, osteoporosis, and peptic ulcer disease.


Q: Why is Decortin H sometimes prescribed in combination with other drugs?

Official regulatory documents indicate that because the drug suppresses the immune system, a concomitant antimicrobial drug may be used when this immunosuppression is considered clinically significant in certain conditions.


Q: Are there specific side effects Decortin H users should watch out for if they have diabetes?

The primary warning for users with diabetes is the risk of developing hyperglycemia (high blood sugar). This may necessitate an adjustment in the use of insulin or other blood glucose management agents.


Q: What general expectations should users have about Decortin H's efficacy?

The official protocol states that the initial dosage should be adjusted and maintained until a satisfactory clinical response is noted. If a satisfactory response is not achieved, regulatory documents describe that the drug may be considered for discontinuation.


Q: How long does Decortin H stay in the body after the last dose?

Prednisolone, the active form of the drug, has an estimated elimination half-life of approximately 3 to 4 hours. The drug is typically considered to be eliminated from the system within about 16.5 to 22 hours after the last dose.


Q: What are the main research themes concerning Decortin H's use in children?

Official documents highlight safety themes for long-term administration in children. These include the potential for growth retardation and the necessity for monitoring the child's growth and development during treatment.

How should Decortin H be stored and disposed of?

Decortin H Storage and Disposal

Official regulatory guidelines establish specific requirements for storing and disposing of Decortin H (prednisolone) oral tablets to maintain stability and ensure safety.

Storage Requirements

  • Temperature and Protection: The medicine must be stored at a temperature not exceeding 30 C and protected from light and moisture.
  • Child Safety: It is mandatory to keep this medicine out of the sight and reach of children.
  • Container: Tablets should be kept in the original, securely sealed container.

Disposal Instructions

Expired or unused Decortin H must not be disposed of in household waste or flushed down the toilet. Consult a pharmacist for instructions on proper disposal, such as participation in a drug take-back program, to comply with environmental protection requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Decortin H found in:

A-Z Index: